| ²é¿´: 347 | »Ø¸´: 1 | |||
ÂäÑ©º¬Ïã½ð³æ (ÕýʽдÊÖ)
|
[½»Á÷]
¡¾ÇóÖú¡¿Õâ¾ä»°Ôõô·Ò루ÎÒ²»ÖªµÀ·¢µ½Äĸö°æ¿é£© ÒÑÓÐ1È˲ÎÓë
|
|
Its major drawback is dose-limiting systemic toxicity of the therapeutic agents. ´ó¼Ò°ïÎÒ·Òëһϣ¬µ¥¸ö´ÊÎÒµ¹ÊÇ»á·Ò룬Á¬³ÉÒ»¸öͨ˳µÄ¾ä×Ó¸ÃÊÇÊ²Ã´ÄØ£¿ |
» ²ÂÄãϲ»¶
071000ÉúÎïѧÇóµ÷¼Á£¬³õÊԳɼ¨343
ÒѾÓÐ7È˻ظ´
0703»¯Ñ§µ÷¼Á£¬Çóµ¼Ê¦ÊÕ
ÒѾÓÐ8È˻ظ´
0856²ÄÁÏ»¯¹¤µ÷¼Á ×Ü·Ö330
ÒѾÓÐ11È˻ظ´
±¾¿ÆÐÂÄÜÔ´¿ÆÑ§Ó빤³Ì£¬Ò»Ö¾Ô¸»ªÀíÄܶ¯285Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085600£¬×¨Òµ¿Î»¯¹¤ÔÀí£¬321·ÖÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁϹ¤³Ì294Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
295²ÄÁϹ¤³Ìר˶Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
305Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ʳƷ¹¤³Ìר˶һ־ԸÖк£Ñó309Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
jxf8257
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 987.1
- É¢½ð: 40
- Ìû×Ó: 495
- ÔÚÏß: 30Сʱ
- ³æºÅ: 660305
- ×¢²á: 2008-11-23
- רҵ: Ò©Îﻯѧ
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
| ¸ÃÖÎÁÆÊÔ¼ÁµÄÖ÷ҪȱµãÊǼÆÁ¿ÏÞÖÆµÄϵͳ¶¾ÐÔ |
2Â¥2010-06-02 18:37:35














»Ø¸´´ËÂ¥